Novel Therapies for Hard-To-Treat Diseases with Boehringer Ingelheim
Posted: 12 May 2023 Today we’re pleased to announce a new partnership with Boehringer Ingelheim! Through this partnership, Boehringer Ingelheim will leverage our natural product discovery capabilities. The goal is to accelerate their discovery and development of novel therapeutic…
Clinical trial of inhaled oxytocin to reduce maternal mortality underway in Melbourne
Posted: 12 May 2023 A Phase 1 clinical trial led by Monash University to assess the safety and performance of a novel oxytocin inhaler in healthy, non-pregnant female volunteers has commenced in Melbourne. The Inhaled Oxytocin Project, led by Professor…
ACCENT Trial Recruitment Progress
Posted: 12 May 2023 Amplia Therapeutics Limited, is pleased to announce completion of enrolment of the third cohort of patients in the ongoing Phase 1b/2a ACCENT clinical trial in frontline patients with pancreatic cancer. Amplia’s CEO and Managing…
2022 Member Survey results
Posted: 10 May 2023 On 2 December 2022, BioMelbourne Network emailed members, inviting you to complete our 2022 Member Survey which closed on 31 January 2023. We conduct this survey annually and track the trends year on year,…
Kinoxis Therapeutics partners with Boehringer Ingelheim to develop novel treatments for psychiatric patients with social dysfunction symptoms
Posted: 8 May 2023 Kinoxis Therapeutics today announced a strategic partnership and licensing agreement with Boehringer Ingelheim for the development of first-in-class oxytocin targeting precision psychiatry treatments to improve the quality of life of people living with neuropsychiatric…
More than $11M in prestigious grants awarded to researchers to combat antibiotic resistance
Posted: 8 May 2023 The World Health Organization (WHO) has continually highlighted antibiotic resistance as one of today’s most significant threats to the global community. Faced with rapidly growing antibiotic resistance, there is an urgent need to discover…
Study shows benefit of universal genetic testing after breast cancer diagnosis
Posted: 8 May 2023 A study of women recently diagnosed with breast cancer has found many have identifiable and well understood gene abnormalities, and yet they are excluded from subsidised genetic testing that can guide their treatment. At…
ANDHealth’s response to the National Press Club address by the Federal Health Minister, The Hon Mark Butler MP
Posted: 8 May 2023 “We simply cannot build a stronger Medicare without better realising the opportunities that digital health technologies open up for more efficient and collaborative healthcare.” – Mark Butler, National Press Club (2 May 2023). The…
Championing trailblazing women in healthtech
Posted: 8 May 2023 Three extraordinary women, who are driving change in the healthtech industry, are recipients of 2023 BioMelbourne Network Women in Leadership Awards. These innovators and enablers are tenacious risk-takers who are inspiring the next generation…
UBI launches PETRACKR Diabetes product for dogs and cats.
Posted: 4 May 2023 Universal Biosensors, is delighted to announce it has today launched its PETRACKR blood glucose monitoring product for dogs and cats with diabetes globally. To coincide with the launch, UBI announces it has signed three…
ZIRCON Phase III Kidney Cancer Imaging Study Presented at AUA: New Data Confirms Efficacy in Masses 2cm or Smaller
Posted: 4 May 2023 Telix today announces additional positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier: NCT03849118). The results were featured in a late-breaking oral…
First Patients in Canada Imaged with Illuccix
Posted: 4 May 2023 Telix announces first patients have been imaged in Canada with its commercially available prostate cancer imaging agent, Illuccix® [kit for the preparation of gallium (68Ga) PSMA-11 for intravenous injection]. With Illuccix now available nationwide…
